The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1367
June 27, 2011
View Complete Issue         Table of Contents 2019 
Spinosad (Natroba) Topical Suspension for Head Lice
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Spinosad (Natroba) Topical Suspension for Head Lice
June 27, 2011 (Issue: 1367)
The FDA has approved spinosad 0.9% suspension (Natroba – ParaPro) for topical treatment of head lice infestation in patients ≥4 years old. It is available only by prescription.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Spinosad (Natroba) Topical Suspension for Head Lice
Article code: 1367b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.